Nutra Pharma Corp.

Equities

NPHC

US67060U2087

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 14:06:38 2024-05-13 EDT			5-day change	1st Jan Change
0.0001 ^USD	0.00%		0.00%	+9,900.00%

03-22	Nutra Pharma Corporation Appoints Michael Flax as CFO	CI
03-22	Nutra Pharma Corporation Announces Management Changes	CI

Nutra Pharma Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2019

May 07, 2021 at 07:02 am

Nutra Pharma Corp. announced earnings results for the second quarter ended June 30, 2019. For the second quarter, the company announced sales was USD 10,215 compared to USD 29,381 a year ago. Operating loss was USD 327,846 compared to USD 335,849 a year ago. Net loss was USD 1.668 million compared to USD 1.330 million a year ago. For the half year, sales was USD 51,537 compared to USD 60,357 a year ago. Operating loss was USD 576,784 compared to USD 673,305 a year ago. Net loss was USD 2.068 million compared to USD 2.328 million a year ago.

Latest news about Nutra Pharma Corp.

Nutra Pharma Corporation Appoints Michael Flax as CFO	03-22	CI
Nutra Pharma Corporation Announces Management Changes	03-22	CI
Nutra Pharma Corporation Announces CEO Changes	03-22	CI
Nutra Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-21	CI
Nutra Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-22	CI
Nutra Pharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-20	CI
Nutra Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
Nutra Pharma Corp. Auditor Raises 'Going Concern' Doubt	22-04-14	CI
Nutra Pharma Announces First Manufacturing Agreement	22-03-23	CI
Nutra Pharma Expands Manufacturing Capabilities	22-03-17	CI
Nutra Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-10	CI
Nutra Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2019	21-07-01	CI
Nutra Pharma Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2019	21-05-07	CI
Nutra Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2018	21-02-05	CI
Nutra Pharma Corp. Auditor Raises 'Going Concern' Doubt	21-02-04	CI
Nutra Pharma Announces Availability of Nyloxin on the iRemedy Marketplace	19-05-30	CI
Nutra Pharma and JAH Neal Holdings LLC Sign Definitive Letter of Intent for $4 Million Joint Venture Financing	18-06-28	CI
Nutra Pharma Corporation Partners with NxGen Brands, LLC for Nyloxin Distribution	18-04-19	CI
Nutra Pharma Corp. Auditor Raises 'Going Concern' Doubt	18-04-16	CI
Nutra Pharma Corporation Files Provisional Patent for the Treatment of Amyotrophic Lateral Sclerosis	18-04-10	CI
Nutra Pharma Corp. Announces Resignation of Dan Oran, Director	18-03-07	CI
Nutra Pharma Corporation Signs Definitive Distribution Agreement with Pharmachal PTY LTD	18-02-01	CI
Nutra Pharma Corporation Partners with EuroAmerican IP, LLC to Distribute Nyloxin for Sale to Government Agencies	18-01-18	CI
Nutra Pharma Corp. Launches Luxury Feet	17-06-21	CI
Nutra Pharma Corporation Announces Collaboration with International Security Group to Develop Nerve Agent Counter Measures	17-05-23	CI

Chart Nutra Pharma Corp.

Duration

Period

More charts

Company Profile

Nutra Pharma Corp. is a holding company, which owns intellectual property and operates in the biotechnology industry. The Company conducts drug discovery research and development activities on its own and through its subsidiary, ReceptoPharm, Inc. Its first consumer product, Cobroxin, is an over-the-counter pain reliever designed to treat moderate to severe chronic pain. Its second consumer product, Nyloxin, is an over-the-counter pain reliever that is a stronger version of Cobroxin and is designed to treat severe chronic pain. Pet Pain-Away is an over-the-counter pain reliever designed to treat pain in cats and dogs. Equine Pain-Away is an over-the-counter topical pain reliever designed to treat pain and inflammation in horses. Its Luxury Feet is an over-the-counter pain reliever designed specifically to treat foot pain and inflammation, especially for women who wear high heels and stilettos. The Company also manufactures Cell Defender, ZMUNITY, and Avini Plus Energy, among others.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NUTRA PHARMA CORP.	+9,900.00%	706K
MODERNA, INC.	+29.03%	48.16B
IQVIA HOLDINGS INC.	-0.10%	41.73B
LONZA GROUP AG	+43.45%	41.03B
CELLTRION, INC.	-5.26%	28.77B
ICON PUBLIC LIMITED COMPANY	+11.48%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-22.74%	18.96B
BIO-TECHNE CORPORATION	+9.06%	12.92B
MEDPACE HOLDINGS, INC.	+30.01%	12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.51%	11.77B

Other Biotechnology & Medical Research